Oncolytics Biotech is trading at $0.41 (-8.76%); broad-market pressure is a possible, unconfirmed factor.
- No clear company-specific negative catalyst surfaced for November 5.
- The latest company news was encouraging anal-cancer translational data released November 4, alongside the prior session’s 8.92% gain.
- The decline coincided with a broad market sell-off, while biotech sector performance was positive. No volume details were provided.